Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00144768 · ClinicalTrials.gov registry record · Phase 4
A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients
A Phase 4 study of Mucopolysaccharidosis I and Hurler's Syndrome, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT00144768 is a Phase 4 study of Mucopolysaccharidosis I and Hurler's Syndrome that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 25 participants, below the 72-participant average among 5 other Mucopolysaccharidosis I trials with a reported enrollment target (65% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00144768, a Phase 4 study of Mucopolysaccharidosis I and Hurler's Syndrome, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate.
Conditions Studied
Interventions
- DRUG laronidase
Study Locations (3)
California
- Childrens Hospital Los Angeles - Los Angles
Connecticut
- Connecticut Children's Medical Center - Hartford
Wisconsin
- Children's Hospital of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2004-07 |
| Est. Completion | 2007-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00144768
The ClinicalTrials.gov registry entry for NCT00144768 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 72-participant average among 5 other Mucopolysaccharidosis I trials with a reported enrollment target (65% lower). The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Mucopolysaccharidosis I appearing as the primary indexed condition, and to 1 intervention - of which laronidase is the first listed.
NCT00144768 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Connecticut, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT00144768 about?
NCT00144768 is a clinical study titled "A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG (Glycosaminoglycan) Levels in Aldurazyme® Treated Patients". The purpose of this study is to determine whether the development of antibodies to laronidase in patients with MPS I receiving Aldurazyme® impairs the clearance of GAG substrate.
What is the current status of trial NCT00144768?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2004-07. Estimated completion is 2007-05.
What conditions does trial NCT00144768 study?
This clinical trial studies the following conditions: Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie's Syndrome.
What interventions are being tested in trial NCT00144768?
The interventions under investigation include: laronidase (DRUG).
Who is sponsoring clinical trial NCT00144768?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00144768 being conducted?
This trial has 3 study locations across California, Connecticut, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mucopolysaccharidosis I
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry of Patients Diagnosed With Lysosomal Storage Diseases
RECRUITING
-
Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIX
ACTIVE NOT RECRUITING
-
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
ACTIVE NOT RECRUITING · Phase 1
-
Stem Cell Transplantation for Hurler
COMPLETED · Phase 2
-
Human Placental-Derived Stem Cell Transplantation
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.